Please select the option that best describes you:

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Metastatic

How do you approach second-line therapy for patients with PD-L1 positive metastatic TNBC, after progression on sacituzumab govitecan + pembrolizumab?

Tolaney, et al., PMID: 41564397